Investigating antibiotic dosing in critically ill children on ECMO
Official title: Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation
Run by University Hospital, Ghent · NCT06426836 · Data updated 2026-11-12
This study is testing if the current antibiotic doses are strong enough to help critically ill children on ECMO get better.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 15 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 3 sites (Brussels, Brussels Capital and 2 other locations) |
| Status | Recruiting |
| Started | August 19, 2016 |
| Main results expected | July 1, 2029 |
| Study ends | July 1, 2029 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT06426836 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include neonates, infants, and children aged 1.8 kg to 15 years who are on ECMO and receiving specific antibiotic treatments.
✕Probably not a fit
Patients without a catheter for blood sampling or those with known hypersensitivity to beta-lactam antibiotics and ciprofloxacin may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study examines the pharmacokinetics of various antibiotics in critically ill pediatric patients who are on extracorporeal membrane oxygenation (ECMO). It aims to determine if current dosing regimens for antibiotics such as meropenem, piperacillin-tazobactam, and amoxicillin-clavulanate achieve the necessary pharmacodynamic targets. The research will be conducted in a multicentric clinical setting across several pediatric intensive care units. Blood samples will be collected from patients receiving these antibiotics to assess their effectiveness.
Why it matters
Potential benefit: If successful, this study could optimize antibiotic dosing in critically ill children, improving treatment outcomes.
How similar studies have gone: Other studies have explored antibiotic dosing in pediatric populations, but this specific approach in ECMO patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients admitted to the pediatric intensive care unit or cardiac intensive care unit * patient age : 1,8 kg-15 years * patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin) * intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred) * extracorporeal membrane oxygenation circuit Exclusion Criteria: * no catheter in place for blood sampling * absence of parental/patient consent * known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
Where it's running
-
Queen Fabiola Children's University Hospital
Brussels, Brussels Capital, Belgium Recruiting -
University Hospital
Ghent, Belgium Recruiting -
Universitair hospital
Leuven, Belgium Recruiting
Study contacts
- Principal investigator: Annick de Jaeger, MD — University Hospital, Ghent
- Study coordinator: Pieter De Cock, PharmD
- Email: pieter.decock@uzgent.be
- Phone: +32 9 332 29 69
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding antibiotic dosing in critically ill children
This study is trying to find the best antibiotic doses for critically ill children in the hospital to make sure they get effective treatment with fewer side effects.
-
Precision dosing of beta-lactam antibiotics in critically ill children
This study tests whether using model-informed precision dosing can help critically ill kids reach target antibiotic levels earlier when treated with amoxicillin-clavulanate, piperacillin-tazobactam, or meropenem.
-
Levetiracetam Dosing in Critically Ill on CRRT
This study tests how levetiracetam behaves in the bodies of adults on continuous renal replacement therapy to help figure out the best dosing.
-
Trigonelline Monohydrate for NAD+ Metabolism in Healthy Adults
A small study in healthy adults tests whether taking trigonelline monohydrate by mouth for 4 weeks can change NAD+ levels and how the body handles the supplement, compared with NMN and placebo.
-
Cetuximab bioequivalence test in healthy men
This study tests whether a cetuximab injection is bioequivalent to Erbitux in healthy men to see if they behave the same in the body.
-
GenSci142 as a vaginal treatment for bacterial vaginosis
This study tests whether GenSci142 given as vaginal doses is safe and may help BV patients aged 18–50 compared with clindamycin cream.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.